Requests for no discussion of biosimilars in the Trans-Pacific Partnership meeting

The House Democrats have written President Obama a letter that encourages him to leave all biosimilars discussions out any discussions that will take place.If the discussions were to take place it would conflict with the Fiscal Year 2012 budget proposal.

The Pharma Times stated:
The TTP is a multilateral free trade agreement which the US is currently negotiating with Australia, Brunei, Chile, Malaysia, New Zealand, Peru, Singapore and Vietnam. If the finally-agreed version deal were to include 12 years' exclusivity for biologics, this "would impede the ability of Congress to achieve the Administration's proposed seven-year change without running afoul of US trade obligations," the Democrats warn the President, adding: "we see no reason for the United States to agree to such a provision, much less to propose it."


This September at Business of Biosimilars and Biobetters, representatives from Momenta Pharmaceuticals, Inc., Schiff Hardin LLP and Fish & Richardson will be conducting the workshop Biosimilar IP Protection and Patent Litigation Strategies for Development in the US and Abroad which will examine regulatory and legal affairs, legal counsel and IP/Patent litigation within biosimilar and originator biopharmaceutical and biotech companies. For more information, download the brochure.


Do you believe it is best for Obama to leave biosimilars out of these discussions?  Why or why not?

Share this article with your social network, just click below to share now!

Share |